Join
Live feed
·
PRReleasevia Quantisnow
CASI Pharmaceuticals Inc. logo

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

ByQuantisnow·Wall Street's wire, on your screen.
CASI· CASI Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CASI (CASI Pharmaceuticals Inc.) and more on Quantisnow.